OBR Daily Commentary

forumImage

F.D.A. Nominee Clears Senate Panel

(New York Times) Dec 3, 2019 - A Senate committee on Tuesday advanced the nomination of Dr. Stephen Hahn, a noted radiologist and cancer researcher, to lead the Food and Drug Administration. Dr. Hahn, chief medical executive at the University of Texas M.D. Anderson Cancer Center, was nominated by President Trump last month to replace Dr. Scott Gottlieb, who left the job in April.

Read Article arrow

Howard Sandler, MD, MS, FASTRO (Posted: December 03, 2019)

quotesSteve Hahn is very well regarded in the ASTRO community. He's a radiation oncologist who is also board-certified in medical oncology. He's been chair of rad onc at UPenn and a leader at MD Anderson. The radiation oncology community is excited for Steve as his nomination proceeds thru the regulatory process and we hope that he's confirmed as the next FDA Commissioner.quotes

Add Comment 1 Comment
forumImage

Researchers Assess the Accuracy of 68Ga-PSMA-11 PET in Localizing Prostate Cancer

(UCSF) Apr 8, 2019 - Treatment of patients with biochemically recurrent prostate cancer is guided by disease location and extent.

Read Article arrow

Howard Sandler, MD, MS, FASTRO (Posted: April 08, 2019)

quotesSome of the leaders in the US from UCLA and UCSF report on their Ga68 PSMA PET scan results in prostate cancer patients after surgery, after RT or after both. While PSMA PET has not been formally compared with fluciclovine PET, many expect PSMA PET to be superior imaging modality. Hopefully, we'll see some high quality comparison data and hopefully we'll have access to an FDA-cleared PSMA imaging modality soon.quotes

Add Comment 1 Comment
forumImage

Prophylactic Cranial Irradiation Improves Disease-Free Survival and Brain Metastasis Rates for Locally Advanced Non-Small Cell Lung Cancer

(NRG Oncology) Mar 18, 2019 - Prophylactic cranial irradiation (PCI), a technique used to prevent the clinical development of brain metastases, is established as a standard approach for many patients with small cell lung cancer (SCLC) after initial therapy. While studies established that PCI decreases the incidence of brain metastases for patients with locally advanced non-small cell lung cancer (LA-NSCLC), there is no established indication for its use for such NSCLC patients. Cumulative brain metastases (BM) rates are high for patients with LA-NSCLC. NRG Oncology conducted the NRG-RTOG 0214 trial to address this high incidence of brain metastases and determine if the addition of PCI following primary treatment improved overall survival (OS) in patients with LA-NSCLC.

Read Article arrow

Howard Sandler, MD, MS, FASTRO (Posted: March 19, 2019)

quotesProphylactic cranial irradiation (PCI) is generally offered to patients with limited small cell lung cancer but hasn't been offered to non-small cell lung cancers. This prospective randomized study shows that PCI can alter the pattern of failure and has a large impact on the incidence of brain mets (HR = 0.43) but doesn't improve overall survival. Some toxicity has been reported as well. At this point, there would be little rationale for routine use of PCI in non-small cell lung cancer.quotes

Add Comment 1 Comment

Meet the Editorial Board

Prostate Cancer
member photo
Tomasz M. Beer, MD, FACP

Professor of Medicine, Division of Hematology/Medical O...

Community Oncology
member photo
Dean Gesme, MD

FACP FACPE FASCO President, Minnesota Oncology...

Breast Cancer
member photo
Debu Tripathy, MD

Professor and Chair, Department of Breast Medical Oncol...

Lung Cancer
member photo
H. Jack West, MD

Associate Clinical Professor, Medical Oncology Executi...

Gastrointestinal Cancers
member photo
Howard S. Hochster, MD

Distinguished Professor of Medicine, Rutgers Robert Woo...

Radiation Oncology
member photo
Howard Sandler, MD, MS, FASTRO

Ronald H. Bloom Chair in Cancer Therapeutics
Pr...

Community Oncology
member photo
Jeff Patton, M.D.

CEO Tennessee Oncology...

Precision Medicine Section Editor
member photo
Jennifer Levin Carter, MD, MPH

Chief Medical Officer and Founder, N-of-One...

Financial Sector
member photo
Michael G. King Jr.

Managing Director and Senior Biotechnology Analyst...

Gastrointestinal Cancers
member photo
Richard Goldberg, MD

Director WVU Cancer Institute Director of Cancer Signa...

Editor-In-Chief
member photo
Robert A. Figlin, MD., FACP

Professor and Director, Division of Hematology Oncology...

Health Policy
member photo
Ted Okon

Executive Director Community Oncology Alliance...

Community Oncology
member photo
Thomas Marsland, MD

Vice President Integrated Community Oncology Network ...

Community Oncology
member photo
William Harwin MD

Florida Cancer Specialists President and Managing Part...

Health Policy
member photo
William McGivney, PhD

National Health Policy Expert...

Payer
member photo
Winston Wong, PharmD

President, W-Squared Group...